SCHEMBL17015895

SCHEMBL17015895

c1ccc(-c2cc3ccc4c5ccccc5n(-c5ccc(-c6ccc7ccc8cccc9ccc6c7c89)cc5)c4c3n2-c2ccccc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HAO1 Q9UJM8 1/20 0.34
▸ APP P05067 1/20 0.33
▸ ERBB2 P04626 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ AHR P35869 1/20 0.33
▸ PDE6D O43924 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ PARP1 P09874 1/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ IL1R1 P14778 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668883 0.94 KDM4E (0.35) KDM4EATML3MBTL1HAO1APP
SCHEMBL17015816 0.89 KDM4E (0.35) KDM4EATML3MBTL1HAO1APP
SCHEMBL17015894 0.87 L3MBTL1 (0.39) KDM4EATML3MBTL1HAO1APP
SCHEMBL15632271 0.86 L3MBTL1 (0.45) KDM4EATML3MBTL1HAO1APP
SCHEMBL17015892 0.86 KDM4E (0.38) KDM4EATML3MBTL1HAO1APP
SCHEMBL18810621 0.85 KDM4E (0.36) KDM4EATML3MBTL1ERBB2CYP1A2
SCHEMBL17015942 0.85 L3MBTL1 (0.50) KDM4EATML3MBTL1HAO1APP
SCHEMBL18810602 0.84 L3MBTL1 (0.41) KDM4EATML3MBTL1ERBB2CYP1A2
SCHEMBL17015898 0.83 L3MBTL1 (0.41) KDM4EATML3MBTL1HAO1APP
SCHEMBL17015889 0.83 L3MBTL1 (0.41) KDM4EATML3MBTL1HAO1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback